DVN: State-backed pharma with cheap multiples but material earnings-quality and liquidity concerns
Intrinsic value VND 20,850 vs market VND 18,600, implied upside 12.1% (model confidence: low).
Tổng quan doanh nghiệp
Tổng Công ty Dược Việt Nam - CTCP (DVN) is a UPCom-listed pharmaceutical company operating in the 'Dược phẩm' subsector, with a focus on manufacturing, distribution and commercialisation of medicines and healthcare products. Revenue has been broadly flat over 2023-25 at VND 5,583.2 bn (2023), VND 5,521.8 bn (2024) and VND 5,645.6 bn (2025), while reported net profit rose from VND 337.5 bn in 2023 to VND 738.6 bn in 2025, reflecting either margin recovery or one-off items in 2025. The largest shareholder is a state investor (Tổng Công ty Đầu Tư Và Kinh Doanh Vốn Nhà Nước) with 65.0% ownership, which provides franchise stability but also subjects DVN to SOE governance constraints and potential payout/strategic directives.
Luận điểm đầu tư
Valuation: Our blended intrinsic value (DCF 70% / PE 30%) yields VND 20,850 per share versus the match price of VND 18,600, implying 12.1% upside. Key valuation inputs include a WACC of 10.0% and terminal growth of 4.0%. The DCF leg produces an intrinsic of VND 27,798 (rounded) per share and the PE leg VND 53,934 per share before blending. Confidence in the model is low due to forensic and liquidity flags.
Fundamentals and profitability: DVN exhibits attractive accounting returns versus peers: ROE 21.1% and ROA 10.5%, with Net Profit Margin 14.0% and EPS of VND 3,116 per share, while the trailing P/E is 6.0x and P/B 1.2x — multiples that appear inexpensive relative to growth and ROE. However, EV/EBITDA is elevated at 34.8x, suggesting either thin EBITDA or balance-sheet distortions; EBIT margin is only 2.5% which helps reconcile the high EV/EBITDA.
Forensic and execution risk: Forensic scores materially weaken the investment case. Beneish M-Score is -1.5461 (worsened year-over-year by +0.56) — above the typical manipulation threshold (>-1.78) and placing DVN in the 79th percentile among Vietnamese peers. Earnings Quality is 24.7/100 with cash-conversion and revenue-quality sub-scores at 0/100, and Altman Z-Score of 2.32 sits in the grey zone. These flags (listed explicitly in the model's sanity_flags) reduce conviction and increase the probability that reported profits may not be sustainable.
Liquidity, ownership and marketability: Trading liquidity is low (avg vol 2w: 18,825 shares) and foreign ownership room is zero, limiting incremental demand from foreign investors. State ownership (65.0%) stabilises control but concentrates governance risk and can limit minority returns. Given the 12.1% implied upside and low model confidence, the upside is modest relative to the forensic and liquidity risks.
Bình luận định giá
Blended intrinsic value using a DCF (70%) and a PE multiple approach (30%). DCF uses a 10.0% WACC and 4.0% terminal growth; PE leg uses a fair PE of 17.31 with a PE cap of 25.
- WACC 10.0% and terminal growth 4.0% drive the DCF present value and the share of terminal value (TV accounts for ~57.07% of value).
- Base free cash flow input: VND 468.1 bn (model base_fcf).
- Net debt of ~VND 1.5 trillion reduces equity value in the DCF.
- Blend weights: DCF 70% / PE 30% produced a raw intrinsic of VND 35,638.3 per share before isotonic calibration to VND 20,850.
- Sanity flags (low liquidity, low earnings quality, manipulation risk) led to a low confidence calibration.
The model implies limited upside (12.1%) at the current market price; given the low confidence and forensic flags, the calibrated intrinsic should be treated cautiously. The DCF is sensitive to WACC and terminal growth; earnings-quality concerns and low cash conversion materially lower conviction in the headline intrinsic.
Quan điểm tích cực và tiêu cực
- Relatively high reported ROE of 21.1% and ROA of 10.5% indicate the business can generate solid return on capital versus peers.
- Cheap headline multiples: P/E 6.0x and P/B 1.2x could support rerating if earnings quality and cash conversion improve.
- Recent net profit jump to VND 738.6 bn in 2025 suggests potential operating leverage or successful restructuring.
- State majority ownership (65.0%) may provide stable access to distribution channels and preferential procurement in domestic markets.
- Forensic red flags: Beneish M-Score -1.5461 (above manipulation threshold) and Earnings Quality 24.7/100 suggest reported profits may be overstated or not cash-backed.
- Zero foreign ownership room and low two-week average volume (18,825) limit investor base and liquidity, suppressing rerating potential.
- Elevated EV/EBITDA at 34.8x vs low EBIT margin (2.5%) points to weak cash EBITDA or balance-sheet distortions that could compress valuations.
- Net debt of roughly VND 1.5 trillion and an Altman Z-Score of 2.32 (grey zone) increase financial-risk vulnerability under stress scenarios.
Bối cảnh ngành
The Vietnamese pharmaceuticals sector operates under VAS accounting conventions and significant State influence in procurement and distribution. SBV macro policies and healthcare budget allocations indirectly affect demand for domestically produced medicines. SOE-dominated companies frequently face mandated payout or strategic priorities, and state ownership can both support market access and hinder minority shareholder returns. Peer universe shows median implied upside ~12.0% (351 peers), putting DVN close to the sector median on upside but with lower confidence due to forensic concerns. Domestic peer variance is wide: top sector peers show up to ~36.3% implied upside while bottom peers have double-digit downside risks.
Yếu tố rủi ro
- Earnings manipulation risk: Beneish M-Score -1.5461 (worse year-on-year) and low Earnings Quality (24.7/100) raise the probability of aggressive accruals or one-offs.
- Poor cash conversion: reported profits are not matched by cash flow quality (cash-conversion sub-score 0/100), increasing the risk of profit reversals.
- Liquidity and marketability: two-week avg volume 18,825 and zero foreign room constrain re-rating and make position liquidation harder.
- Concentrated state ownership (65.0%) can result in strategic decisions that deprioritise minority returns or prompt non-commercial transactions.
- Balance sheet and solvency: net debt near VND 1.5 trillion and Altman Z-Score 2.32 imply moderate financial stress risk under adverse scenarios.
- High EV/EBITDA (34.8x) vs low EBIT margin (2.5%) — valuation vulnerable to small EBITDA downgrades.
- Low dividend yield (0.0%) reduces total-return potential for income-oriented investors.
Yếu tố xúc tác
- Release of audited cash-flow statement showing improved cash conversion and operating cash flow growth.
- Reduction in forensic/earnings-quality flags (improvement in Beneish and Earnings Quality metrics) driven by cleaner accruals.
- Operational improvements or margin expansion communicated in quarterly updates that lift EBIT margin above current 2.5%.
- Corporate actions that increase free-float or open foreign ownership room, attracting more institutional capital.
Đánh giá pháp y tài chính
Forensic indicators are the primary concern. Beneish M-Score is -1.5461 — above the common manipulation threshold of -1.78 and up +0.56 year-on-year, signalling rising manipulation risk. Earnings Quality is very low at 24.7/100, with specific weaknesses in cash conversion and revenue quality (both flagged 0/100). Altman Z-Score of 2.32 sits in the grey zone. While state ownership (65.0%) provides some operational continuity, it does not mitigate the forensic flags and may complicate transparency. Overall, forensic risk is moderate but elevated enough to materially lower conviction in reported earnings and the intrinsic estimate.
Lịch sử dự báo
This model's historical track record for DVN is weak: over 10 years the hit rate is 22.2% with an average forward return of -2.5%, suggesting limited historical predictive power. Use model outputs cautiously and prioritise contemporaneous forensic and cash-flow evidence over historical upside statistics.
Được viết bởi mô hình ngôn ngữ ngày 2026-08-10 dựa trên kết quả mô hình và báo cáo tài chính của chính trang này, và có thể trích dẫn số liệu tại thời điểm đó. Đây là phân tích mô tả, không phải khuyến nghị đầu tư — không đưa ra hay hàm ý bất kỳ khuyến nghị mua, bán hay nắm giữ nào.